Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Allergan eyelash product granted approval

Allergan eyelash product granted approval

29th December 2008

Allergan has said its Latisse (bimatoprost ophthalmic solution) 0.03 per cent eyelash product has received approval.

Noting the treatment generated full results within 16 weeks, the company said the drug is designed to be applied once a day to increase fullness and thickness of eyelashes.

The product is aimed primarily at helping those with hypotrichosis, a condition that can cause not enough eyelashes to grow.

Expected to be launched in the first quarter of next year, sales are hoped to reach $500 million (340 million pounds).

Scott Whitcup, executive vice-president of research and development at Allergan, said the product “fulfills a significant and previously unmet need”.

He went on to note Latisse “exemplifies” the company’s commitment to developing treatments in clinical trials.

The product was tested in a phase III, double-masked, multi-centre, placebo-controlled study, which examined its efficacy and safety for use.

One of the ingredients in the drug, bimatoprost, is a structural prostaglandin analog, which is designed to lower intraocular pressure or hypertension within the eye.

Steven Fagien, Latisse clinical investigator, noted: “In the clinical study with Latisse, I observed statistically significant differences in eyelash growth and resulting patient satisfaction.”

Formed in 1948 by Gavin Herbert and Stanley Bly, Allergan now has products for treatments in urologics, medical dermatology, neurosciences, eye care, medical aesthetics and obesity intervention.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.